首页> 外文期刊>Oncology letters >Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient
【24h】

Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient

机译:甲磺酸伊马替尼耐药的慢性粒细胞白血病患者在两个等中心费城染色体上的BCR-ABL融合基因的多个副本

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The so-called Philadelphia (Ph) chromosome is present in more than 90% of chronic myeloid leukemia (CML) cases. Amplification or duplication of the BCR-ABL gene has been found to be one of the key factors leading to drug resistance to imatinib mesylate (IM). In the present study, we identified the presence of isodicentric Ph chromosomes [idic(Ph)] in an IM-resistant patient. Fluorescence in situ hybridization (FISH) analysis on metaphase chromosomes confirmed the heterogeneity and amplification of the fused BCR-ABL gene. FISH analysis superimposed on G-banding confirmed the presence of idic(Ph) chromosomes. Reverse transcription-polymerase chain reaction (RT-PCR) products. revealed the presence of the BCR-ABL fusion transcript b3a2. The idic(Ph) chromosomes in CML were shown to be fused at the satellite regions of the, short arms. The patient did not respond to IM chemotherapy and did not achieve remission. In this study, the impact of the idic(Ph) chromosomes on genomic instability, heterogeneity and amplification of the BCR-ABL gene in IM-resistant patients is discussed.
机译:超过90%的慢性粒细胞白血病(CML)病例中都存在所谓的费城(Ph)染色体。已经发现,BCR-ABL基因的扩增或复制是导致对甲磺酸伊马替尼(IM)产生耐药性的关键因素之一。在本研究中,我们确定了在IM耐药患者中存在等中心Ph染色体[idic(Ph)]。对中期染色体的荧光原位杂交(FISH)分析证实了融合的BCR-ABL基因的异质性和扩增。重叠在G条带上的FISH分析证实了idic(Ph)染色体的存在。逆转录聚合酶链反应(RT-PCR)产品。揭示了BCR-ABL融合转录本b3a2的存在。 CML中的id(Ph)染色体显示在短臂的卫星区域融合。患者对IM化疗无反应,也未达到缓解。在这项研究中,讨论了id(Ph)染色体对IM耐药患者基因组不稳定性,BCR-ABL基因的异质性和扩增的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号